| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8785737 | Cancer Treatment and Research Communications | 2018 | 7 Pages |
Abstract
Within this large cohort of T1a/b N0 breast cancers from the CCR, HER2+ tumors were associated with a significantly worse BCSS in the era before adjuvant trastuzumab. A balanced discussion regarding HER2-directed therapies is needed between patient and clinician.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Mamta Parikh, Maria Galkin, Ann Brunson, Theresa Keegan, Helen K Chew,